Intergenerika’s Dr Axel B. Müller makes an impassioned case against the introduction of a reference pricing system in Switzerland, arguing that it would hurt not only the Swiss generics industry but, ultimately, patients. Dr Müller proposes an alternative way, leveraging the pre-existing system to generate healthcare savings, outlines the dynamics at play in the Swiss generics market today, and argues for the return of essential medicine manufacturing to Europe.
Why should Switzerland import a system that has patently been shown to be wrong-headed elsewhere and that will trigger drug shortages?
